These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Personal experience with ITF 1117 in vaginitis, especially in that caused by Candida albicans]. Donini G, Balbi F, Giulini N. Minerva Ginecol; 1978 Dec; 30(12):1187-92. PubMed ID: 740337 [No Abstract] [Full Text] [Related]
24. In vitro effect of fibrinogen on Candida albicans germ tube formation. Rodrigues A, Vaz CP, Mårdh PA, da Fonseca AF, de Oliveira JM. APMIS; 1999 Nov; 107(11):1020-2. PubMed ID: 10598874 [Abstract] [Full Text] [Related]
29. Clinical trials. A new antimonilial drug. A report from the general practitioner research group. Practitioner; 1974 Feb; 212(1268):254-6. PubMed ID: 4610548 [No Abstract] [Full Text] [Related]
30. Evaluation of vaginal antifungal formulations in vivo. McRipley RJ, Erhard PJ, Schwind RA, Whitney RR. Postgrad Med J; 1979 Sep; 55(647):648-52. PubMed ID: 392480 [Abstract] [Full Text] [Related]
31. Terconazole for the treatment of vulvovaginal candidiasis. Thomason JL, Gelbart SM, Kellett AV, Scaglione NJ, Gotwalt KT, Broekhuizen FF. J Reprod Med; 1990 Nov; 35(11):992-4. PubMed ID: 2277372 [Abstract] [Full Text] [Related]
37. Efficacy of antifungal agents in the cornea. II. Influence of corticosteroids. O'Day DM, Ray WA, Robinson R, Head WS. Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):331-5. PubMed ID: 6321389 [Abstract] [Full Text] [Related]